The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

2.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

3.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

4.

Belzutifan Plus Pembro Approved for Adjuvant RCC

5.

investigating radiation oncology applications of artificial general intelligence.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot